Skip to main content
SpringerLink
Log in

Tumor Necrosis Factor and Cancer

  • Chapter
Cytokines in the Genesis and Treatment of Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Tumor necrosis factor a (TNF) is a potent, pleiotropic, proinflammatory cytokine that is produced by macrophages, neutrophils, fibroblasts, keratinocytes, NK, T-and B-cells and also by tumor cells. TNF binds to either of two receptors, TNF-R1 or TNF-R2, expressed on virtually all mammalian cell types. TNF was named because of its ability, when administered in pharmacologic doses, to cause necrosis of tumors in experimental models. Recombinant TNF is approved in Europe to be given locoregionally as a therapy for sarcoma. TNF produced by the body mediates host responses in acute and chronic inflammatory conditions and aids in host protection from infection and malignancy. The biology of the TNF/TNF-receptor system was reviewed by Palladino et al. 2003 (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: The next generation. Nat Rev Drug Discov 2003;2(9):736–746.

    Article  CAS  PubMed  Google Scholar 

  2. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13(2):135–141.

    Article  CAS  PubMed  Google Scholar 

  3. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72(9):3666–3670.

    Article  CAS  PubMed  Google Scholar 

  4. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 1984;312(5996):724–729.

    Article  CAS  PubMed  Google Scholar 

  5. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 2003;3(9):745–756.

    Article  CAS  PubMed  Google Scholar 

  6. Feldmann M, Brennan FM, Paleolog E, et al. Anti-TNFalpha therapy of rheumatoid arthritis: What can we learn about chronic disease? Novartis Found Symp 2004;256:53–69; discussion-73, 106–111, 266–269.

    Article  CAS  PubMed  Google Scholar 

  7. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000; 165(10):5780–5787.

    CAS  PubMed  Google Scholar 

  8. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385(6618):729–733.

    Article  CAS  PubMed  Google Scholar 

  9. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385(6618):733–736.

    Article  CAS  PubMed  Google Scholar 

  10. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987;262(15):6951–6954.

    CAS  PubMed  Google Scholar 

  11. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990;63(2):251–258.

    Article  CAS  PubMed  Google Scholar 

  12. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 1998;95(2):570–575.

    Article  CAS  PubMed  Google Scholar 

  13. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993;268(25): 18542–18548.

    CAS  PubMed  Google Scholar 

  14. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 1998;28(l):257–263.

    Article  CAS  PubMed  Google Scholar 

  15. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998;281(5381): 1305–1308.

    Article  CAS  PubMed  Google Scholar 

  16. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11(9):372–377.

    Article  CAS  PubMed  Google Scholar 

  17. Schutze S, Machleidt T, Adam D, et al. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem 1999;274(15):10203–10212.

    Article  CAS  PubMed  Google Scholar 

  18. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114(2):181–190.

    Article  CAS  PubMed  Google Scholar 

  19. Legier DF, Micheau O, Doucey MA, Tschopp J, Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 2003;18(5):655–664.

    Article  Google Scholar 

  20. Lejeune FJ. Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002;110(4):433–435.

    Article  CAS  PubMed  Google Scholar 

  21. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4(7):429–437.

    Article  PubMed  Google Scholar 

  22. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4(4):408–414.

    Article  CAS  PubMed  Google Scholar 

  23. Folli S, Pelegrin A, Chalandon Y, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993;53(5): 829–836.

    Article  CAS  PubMed  Google Scholar 

  24. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003;9(12):4537–4545.

    CAS  PubMed  Google Scholar 

  25. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol 2004;22(4):592–601.

    Article  CAS  PubMed  Google Scholar 

  26. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110(4):475–482.

    Article  CAS  PubMed  Google Scholar 

  27. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 2004;64(2):565–571.

    Article  CAS  PubMed  Google Scholar 

  28. Borsi L, Balza E, Carnemolla B, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003;102(13):4384–4392.

    Article  CAS  PubMed  Google Scholar 

  29. Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-alpha increases human melanoma cell invasion and migration in vitro: The role of proteolytic enzymes. Br J Cancer 2003;89(6): 1123–1129.

    Article  CAS  PubMed  Google Scholar 

  30. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-(R) dependent upregulation of matrix metalloproteases. Carcinogenesis 2004:bghl46.

    Google Scholar 

  31. Mochizuki Y, Nakanishi H, Kodera Y, et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 2004;21(l):39–47.

    Article  CAS  PubMed  Google Scholar 

  32. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987;84(15):5277–5281.

    Article  CAS  PubMed  Google Scholar 

  33. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992;140(3):539–544.

    CAS  PubMed  Google Scholar 

  34. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: A potential target for the therapy of solid tumours. Lancet Oncol 2003;4(9):565–573.

    Article  CAS  PubMed  Google Scholar 

  35. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4(l):11–22.

    Article  CAS  PubMed  Google Scholar 

  36. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000;78(10):554–561.

    Article  CAS  PubMed  Google Scholar 

  37. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 2001;21(2B):1355–1358.

    CAS  PubMed  Google Scholar 

  38. Yoshida N, Ikemoto S, Narita K, et al. Interleukin-6, tumour necrosis factor alpha and interleukinlbeta in patients with renal cell carcinoma. Br J Cancer 2002;86(9): 1396–1400.

    Article  CAS  PubMed  Google Scholar 

  39. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998;77(12):2246–2251.

    CAS  PubMed  Google Scholar 

  40. Partanen R, Koskinen H, Hemminki K. Tumour necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer. Occup Environ Med 1995;52(5):316–319.

    Article  CAS  PubMed  Google Scholar 

  41. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Jr., Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003;97(5):1211–1216.

    Article  CAS  PubMed  Google Scholar 

  42. Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 1998;4(7): 1743–1748.

    CAS  PubMed  Google Scholar 

  43. Bossola M, Muscaritoli M, Bellantone R, et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest 2000;30(12):1107–1112.

    Article  CAS  PubMed  Google Scholar 

  44. von Biberstein SE, Spiro JD, Lindquist R, Kreutzer DL. Enhanced tumor cell expression of tumor necrosis factor receptors in head and neck squamous cell carcinoma. Am J Surg 1995; 170(5):416–422.

    Article  Google Scholar 

  45. Ariapart P, Bergstedt-Lindqvist S, van Harmelen V, Permert J, Wang F, Lundkvist I. Resection of pancreatic cancer normalizes the preoperative increase of tumor necrosis factor alpha gene expression. Pancreatology 2002;2(5):491–494.

    Article  CAS  PubMed  Google Scholar 

  46. Li R, Ruttinger D, Si LS, Wang YL. Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbecks Arch Surg 2003;388(6):406–412.

    Article  PubMed  Google Scholar 

  47. Boldrini L, Calcinai A, Samaritani E, et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: Putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000;83(4):480–486.

    Article  CAS  PubMed  Google Scholar 

  48. Wang YY, Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI. Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 2003;66(10):593–598.

    PubMed  Google Scholar 

  49. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90(12):2312–2316.

    CAS  PubMed  Google Scholar 

  50. Marsh HP, Haldar NA, Bunce M, et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 2003; 89(6): 1096–1101.

    Article  CAS  PubMed  Google Scholar 

  51. Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod 2003;18(8):1681–1685.

    Article  CAS  PubMed  Google Scholar 

  52. Ness RB. Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. Am J Obstet Gynecol 2003; 189(1): 280–294.

    Article  PubMed  Google Scholar 

  53. Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-alpha in Barrett’s oesophagus: A potential novel mechanism of action. Oncogene 2002;21(39):6071–6081.

    Article  CAS  PubMed  Google Scholar 

  54. Fujiki H, Suganuma M, Okabe S, Kurusu M, Imai K, Nakachi K. Involvement of TNF-alpha changes in human cancer development, prevention and palliative care. Mech Ageing Dev 2002;123(12): 1655–1663.

    Article  CAS  PubMed  Google Scholar 

  55. Arnott CH, Scott KA, Moore RJ, et al. Tumour necrosis factor-alpha mediates tumour promotion via aPKC alphaand AP-1-dependent pathway. Oncogene 2002;21(31):4728–4738.

    Article  CAS  PubMed  Google Scholar 

  56. Scott KA, Moore RJ, Arnott CH, et al. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003;2(5):445–451.

    CAS  PubMed  Google Scholar 

  57. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 2004;23(10):1902–1910.

    Article  CAS  PubMed  Google Scholar 

  58. Tsimberidou AM, Giles FJ. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2002;2(3):277–286.

    Article  CAS  PubMed  Google Scholar 

  59. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: Personalized molecular medicine. Jama 2001;286(18):2211–2214.

    Article  CAS  PubMed  Google Scholar 

  60. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100(4):1215–1219.

    CAS  PubMed  Google Scholar 

  61. Stasi R, Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 2002;116(2):334–337.

    CAS  PubMed  Google Scholar 

  62. Raza A, Lisak LA, Tahir S, et al. Hematologic improvement in response to anti-tumor necrosis factor (TNF) therapy with Remicade® in patients with myelodysplastic syndromes (MDS). ASH 44th Annual Meeting; 6–10 December 2002; Philadelphia, PA.

    Google Scholar 

  63. Eisen T, Boshoff C, Mak I, et al. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82(4):812–817.

    Article  CAS  PubMed  Google Scholar 

  64. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alphal-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A 1996;93(15):7552–7556.

    Article  CAS  PubMed  Google Scholar 

  65. Maisey NR, Hall K, Lee C, et al. Infliximab: A phase II trial of the tumour necrosis factor (TNFa) monoclonal antibody in patients with advanced renal cell cancer (RCC). 40th ASCO Annual Meeting; June 5–8, 2004; New Orleans, LA.

    Google Scholar 

  66. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: A cohort study. Blood 2003;102(8):2768–2776.

    Article  CAS  PubMed  Google Scholar 

  67. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgGl-Fc fusion complex therapy. J Am Acad Dermatol 2001;45(6):953–956.

    Article  CAS  PubMed  Google Scholar 

  68. Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 31):S203–208.

    CAS  PubMed  Google Scholar 

  69. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-TNF therapy in 18,572 patients. Arthritis Rheum, p. suppl. S242.

    Google Scholar 

  70. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46(10):2565–2570.

    Article  CAS  PubMed  Google Scholar 

  71. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46(12):3151–3158.

    Article  CAS  PubMed  Google Scholar 

  72. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48(2):319–324.

    Article  CAS  PubMed  Google Scholar 

  73. Colombel JF, Loftus EV, Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004;126(l):19–31.

    Article  CAS  PubMed  Google Scholar 

  74. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92(6 Suppl):1684–1688.

    Article  CAS  PubMed  Google Scholar 

  75. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5(4):375–388.

    Article  CAS  PubMed  Google Scholar 

  76. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS, Jr. NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 2000;289(5488): 2363–2366.

    Article  CAS  PubMed  Google Scholar 

  77. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2(11):862–871.

    Article  CAS  PubMed  Google Scholar 

  78. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003;6(4):401–406.

    Article  CAS  PubMed  Google Scholar 

  79. Tobinick EL. Targeted etanercept for treatment-refractory pain due to bone metastasis: Two case reports. Clin Ther 2003;25(8):2279–2288.

    Article  PubMed  Google Scholar 

  80. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003;9(5):292–303.

    Article  CAS  PubMed  Google Scholar 

  81. Couriel DR, Saliba R, Hicks K, et al. TNF-Alpha Inhibition for the Treatment of Chronic GVHD. ASH 44th annual meeting; 6–10 December 2002; Philadelphia, PA.

    Google Scholar 

  82. Campos A, Vaz CP, Costa N, et al. Infliximab as Salvage Therapy for Patients with Acute Graft Versus Host Disease Refractory to Steroids. ASH 45th Annual Meeting; 6–9 December 2003; San Diego, CA.

    Google Scholar 

  83. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroidrefractory acute GVHD: A case series. Am J Hematol 2003;74(2):119–124.

    Article  PubMed  Google Scholar 

  84. Rube CE, van Valen F, Wilfert F, et al. Ewing’s sarcoma and peripheral primitive neuroectodermal tumor cells produce large quantities of bioactive tumor necrosis factor-alpha (TNF-alpha) after radiation exposure. Int J Radiat Oncol Biol Phys 2003;56(5):1414–1425.

    Article  CAS  PubMed  Google Scholar 

  85. Rube CE, Wilfert F, Uthe D, et al. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 2002;64(2): 177–187.

    Article  CAS  PubMed  Google Scholar 

  86. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21(13):2545–2550.

    Article  CAS  PubMed  Google Scholar 

  87. Okunieff P, Augustine E, Hicks JE, et al. Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 2004;22(11):2207–2213.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Hematology/Oncology Research, Centocor Inc., Malvern, PA

    Mark De Witte DVM (Director)

  2. Immunobiology Research, Centocor Inc., Malvern, PA

    David J. Shealy PHD (Associate Director)

  3. Oncology Research, Centocor Inc., Malvern, PA

    Marian T. Nakada PHD (Senior Director) & G. Mark Anderson PHD (Assistant Director)

Authors
  1. Mark De Witte DVM
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Shealy PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marian T. Nakada PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Mark Anderson PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Ohio State University Comprehensive Cancer Center, Columbus, OH

    Michael A. Caligiuri MD

  2. University of Pittsburgh Cancer Center, Pittsburgh, PA

    Michael T. Lotze MD (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

De Witte, M., Shealy, D.J., Nakada, M.T., Anderson, G.M. (2007). Tumor Necrosis Factor and Cancer. In: Caligiuri, M.A., Lotze, M.T. (eds) Cytokines in the Genesis and Treatment of Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-455-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-455-1_4

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-820-2

  • Online ISBN: 978-1-59745-455-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation